Blood loss
Drug research and approvals for blood loss: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 16, 2026, 857 studies of blood loss are recruiting on ClinicalTrials.gov, Health Canada has authorized 6 drug trials for it since 2013, and FDA has 1 approved and 0 open orphan designations naming it.
- Recruiting worldwide: 857
- Trials authorized in Canada: 6
- FDA orphan approvals: 1
- EU medicines: 0
Recruiting Now
Newest start dates first, of 857 recruiting on ClinicalTrials.gov ↗- Pharmacokinetics Of Emulsified Avacopan Applied By NG TubeNCT07556484 · Phase 1 · Mayo Clinic · starts Aug 1, 2027
- Interfacing With NeuroTechnology to Expand Neural Throughput (INTENT)NCT07521930 · Not applicable · Johns Hopkins University · starts Jan 1, 2027
- Optimizing Referral Pathways for Patients With Hematuria and Moderate-Severe ProteinuriaNCT07431931 · Not applicable · Geisinger Clinic · starts Nov 1, 2026
- Sleep to Predict Recovery In Unconscious Patients With Acute Brain InjuryNCT07794605 · Not reported · Columbia University · starts Oct 30, 2026
- A Phase 3 Evaluation of Sutacimig in Glanzmann ThrombastheniaNCT07935356 · Phase 3 · Hemab ApS · starts Oct 27, 2026
- Smartphone Enabled Detection of Cognitive Motor Dissociation in the ICUNCT07917728 · Not reported · Columbia University · starts Oct 27, 2026
- TGD001 Treatment in Thrombotic MicroangiopathiesNCT07459114 · Phase 1 / Phase 2 · TargED Biopharmaceuticals B.V. · starts Oct 25, 2026
- A Study to Assess the Safety of Marstacimab and How Well it Works in People With Mild to Moderate Hemophilia A or B…NCT07923981 · Phase 3 · Pfizer · starts Oct 23, 2026
- SWITCH: Apixaban vs Vitamin K in HM3NCT07471139 · Phase 3 · Columbia University · starts Oct 15, 2026
- Detection of Blood in the GI Lumen With HemoPill AcuteNCT07868068 · Not applicable · Stony Brook University · starts Oct 1, 2026
Trials Authorized in Canada
Newest first; search them all in Canada trials| Apr 14, 2025 | A randomized, double-blind, multi-center, placebo-controlled, parallel-group phase 3 study to compare the efficacy, acceptability, and safety of tranexamic…TRANEXAMIC ACID | HYLORIS DEVELOPMENTS SA | Ongoing |
| Jul 18, 2024 | Astat: arthroplasty of the shoulder using tranexamic acid trialTRANEXAMIC ACID | DR STEPHANE PELET | Pending |
| May 13, 2024 | Bleeding reduction in acute and chronic kidney patients having surgery (brackets) pilot trialTRANEXAMIC ACID / DESMOPRESSIN | HAMILTON HEALTH SCIENCES CORPORATION | Ongoing |
| Feb 8, 2024 | The effects of intraoperative tranexamic acid on perioperative bleeding in craniotomiesTRANEXAMIC ACID | DR. STEPHEN LOWNIE | Ongoing |
| Jun 27, 2019 | Decreasing postoperative blood loss by topical vs. intravenous tranexamic acid in open cardiac surgery (deposition) trialTRANEXAMIC ACID | HAMILTON HEALTH SCIENCES CORPORATION | Ongoing |
| Oct 26, 2017 | Does intravenous tranexamic acid reduce blood loss during vaginectomy? a double-blind,TRANEXAMIC ACID | MOUNT SINAI HOSPITAL | Closed |
FDA Orphan Designations
Approved first, then open designations, newest first| Date | Drug | Sponsor | Status |
|---|---|---|---|
| Dec 29, 1993 | TrasylolFor prophylactic use to reduce perioperative blood loss and the homologous blood transfusion requirement in patients undergoing… | Bayer Corporation | Approved |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA